Search

Displaying results 771 - 780 of 10000 in total
  1. Drug

    Omega-3-acid ethyl esters

    go.drugbank.com/drugs/DB09539
    ApprovedInvestigational

    triglyceride levels in adults with severe (≥ 500 mg/dL) hypertriglyceridemia[FDA Label][A176687]. … Omega-3-acid ethyl esters are prescription drugs that contain eicosapentaenoic acid-ethyl ester (EPA) and docosahexaenoic acid-ethyl ester (DHA) that are used in combination with changes in diet to lower

    Mixtures: Mi-Omega NFProducts: OMACOR 1000 mg Weichkapseln, Zodin 1000 mg - Weichkapseln
  2. Drug

    Econazole

    go.drugbank.com/drugs/DB01127
    Approved

    A broad spectrum antimycotic with some action against Gram positive bacteria. It is used topically in dermatomycoses also orally and parenterally.

    Categories: Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP3A InhibitorsProducts: Pevaryl 10 mg/g Creme, Gyno-Pevaryl 10 mg/g Vaginalcreme
  3. Drug

    Mivacurium

    go.drugbank.com/drugs/DB01226
    ApprovedWithdrawn

    It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission.

    Products: MIVACRON INJECTION 10 mg/5 ml, MİVACRON 10 MG/5 ML ENJEKSİYONLUK ÇÖZELTİ, 5 ADET
  4. Drug

    Paroxetine

    go.drugbank.com/drugs/DB00715
    ApprovedInvestigational

    [T653] It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham. … Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class.

    Synonyms: (3S-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidineCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Cytochrome P-450 Substrates
  5. Drug

    Rabeprazole

    go.drugbank.com/drugs/DB01129
    ApprovedInvestigational

    Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric...

    Mixtures: RASOFORCE 20/1680 MG TOZ İÇEREN SAŞE, 14 SAŞE, RASOFORCE 20/1680 MG TOZ İÇEREN SAŞE, 28 SAŞECategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inducers
  6. Drug

    Botulinum toxin type A

    go.drugbank.com/drugs/DB00083
    ApprovedInvestigational

    In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use.

    Products: BOTOX 100 U. ENJEKSİYONLUK ÇÖZELTİ İÇİN LİYOFİLİZE TOZ, 1 ADET, NEURONOX® 100 UI
  7. Drug

    Asfotase alfa

    go.drugbank.com/drugs/DB09105
    ApprovedInvestigational

    By replacing deficient ALP, treatment with Asfotase Alfa aims to improve the elevated enzyme substrate levels and improve the body's ability to mineralize bone, thereby preventing serious skeletal and … Asfotase alfa is a first-in-class bone-targeted enzyme replacement therapy designed to address the underlying cause of hypophosphatasia (HPP)—deficient alkaline phosphatase (ALP).

    Products: STRENSİQ 40 MG/1.0 ML ENJEKSİYONLUK ÇÖZELTİ, 12 ADET, STRENSİQ 80 MG/0.8 ML ENJEKSİYONLUK ÇÖZELTİ, 12 ADET
  8. Drug

    Fosaprepitant

    go.drugbank.com/drugs/DB06717
    ApprovedInvestigational

    Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment.

    Categories: Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 SubstratesProducts: FOSAPRANT 150 MG İ.V. İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ, 1 ADET, FOSEMRED 150 MG/VIAL
  9. Drug

    Pramipexole

    go.drugbank.com/drugs/DB00413
    ApprovedInvestigational

    RLS is a sleep-related disorder characterized by unpleasant sensations in the lower extremities, often accompanied by an uncontrollable urge to move the legs [A176876]. … In addition to the above FDA approval for Parkinson's Disease, pramipexole was also approved by the FDA in 2006 for the treatment of Restless Legs Syndrome (RLS) [A176873].

    Products: MIPEXOBEX TM 1.0 MG, PACTO 0,5 MG TABLET, 100 ADET
  10. Drug

    Ioxitalamic acid

    go.drugbank.com/drugs/DB13444
    ApprovedWithdrawn

    [A27209] It is a first-generation contrast media formed by an ionic monomer with a high osmolarity of 1500-1800 mOsm/kg. … [A33006] Ioxitalamic acid in the salt forms of sodium and meglumine was developed by Liebel-Flarshem Canada Inc and approved by Health Canada in 1995.

    Mixtures: TELEBRIX 35 FLAKON, 100 ML, TELEBRIX 35 FLAKON, 100 MLProducts: TELEBRIX 30 MEGLUMIN FLAKON, 100 ML, TELEBRIX 35 FLAKON, 50 ML